Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal DebtTotal LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cytosorbents (CTSO) Raw Materials (2023 - 2025)

Cytosorbents' Raw Materials history spans 3 years, with the latest figure at $751000.0 for Q4 2025.

  • Quarterly results put Raw Materials at $751000.0 for Q4 2025, up 31.75% from a year ago — trailing twelve months through Dec 2025 was $751000.0 (up 31.75% YoY), and the annual figure for FY2025 was $751000.0, up 31.75%.
  • Raw Materials for Q4 2025 was $751000.0 at Cytosorbents, up from $565000.0 in the prior quarter.
  • In the past five years, Raw Materials ranged from a high of $751000.0 in Q4 2025 to a low of $491000.0 in Q2 2025.
  • The 3-year median for Raw Materials is $567500.0 (2024), against an average of $601601.0.
  • The sharpest move saw Raw Materials fell 16.89% in 2024, then surged 31.75% in 2025.
  • Year by year, Raw Materials stood at $685801.0 in 2023, then fell by 16.89% to $570000.0 in 2024, then skyrocketed by 31.75% to $751000.0 in 2025.
  • According to Business Quant data, Raw Materials over the past three periods came in at $751000.0, $565000.0, and $491000.0 for Q4 2025, Q3 2025, and Q2 2025 respectively.